TY - JOUR
T1 - The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma
AU - Chéry, Lisly
AU - Borregales, Leonardo D.
AU - Fellman, Bryan
AU - Urbauer, Diana L.
AU - Garg, Naveen
AU - Parker, Nathan
AU - Katz, Matthew H.G.
AU - Wood, Christopher G.
AU - Karam, Jose A.
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/10
Y1 - 2017/10
N2 - Objective To examine the effect that neoadjuvant axitinib for the treatment of localized renal cell carcinoma has on body compartment composition. Materials and Methods The study was based on a single-institution, single-arm clinical trial that enrolled 24 patients with locally advanced non-metastatic biopsy-proven clear cell renal cell carcinoma. Patients received axitinib orally for up to 12 weeks. Computed tomography scans were completed before the start of treatment, after 7 weeks of treatment and at the completion of 12 weeks of treatment. Patients underwent nephrectomy after axitinib treatment. The primary outcome of the current study was change in body compartment composition. Secondary outcomes included development of new-onset sarcopenia and changes in body weight. Results A total of 23 patients had a complete set of imaging for evaluation, of which 19 (82.6%) lost weight. Median weight loss was 4.5 kg (P <.001). Seven patients (30.4%) had sarcopenia before treatment, with an additional 5 (21.7%) developing sarcopenia during treatment. Median decrease in skeletal muscle was 2.9 cm2/m2 (P <.001), visceral adipose tissue was 4.9 cm2/m2 (P =.132), and subcutaneous adipose tissue was 1.0 cm2/m2 (P =.043). Ten of the 16 patients (62.5%) without baseline sarcopenia achieved a partial response, whereas only 1 of the 7 patients (14.3%) with baseline pretreatment sarcopenia achieved a partial response (P =.069). Conclusion Neoadjuvant axitinib resulted in a decrease in skeletal muscle and subcutaneous adipose tissue, as well as weight loss. Patients with baseline sarcopenia tended to have a lower response rate to neoadjuvant axitinib.
AB - Objective To examine the effect that neoadjuvant axitinib for the treatment of localized renal cell carcinoma has on body compartment composition. Materials and Methods The study was based on a single-institution, single-arm clinical trial that enrolled 24 patients with locally advanced non-metastatic biopsy-proven clear cell renal cell carcinoma. Patients received axitinib orally for up to 12 weeks. Computed tomography scans were completed before the start of treatment, after 7 weeks of treatment and at the completion of 12 weeks of treatment. Patients underwent nephrectomy after axitinib treatment. The primary outcome of the current study was change in body compartment composition. Secondary outcomes included development of new-onset sarcopenia and changes in body weight. Results A total of 23 patients had a complete set of imaging for evaluation, of which 19 (82.6%) lost weight. Median weight loss was 4.5 kg (P <.001). Seven patients (30.4%) had sarcopenia before treatment, with an additional 5 (21.7%) developing sarcopenia during treatment. Median decrease in skeletal muscle was 2.9 cm2/m2 (P <.001), visceral adipose tissue was 4.9 cm2/m2 (P =.132), and subcutaneous adipose tissue was 1.0 cm2/m2 (P =.043). Ten of the 16 patients (62.5%) without baseline sarcopenia achieved a partial response, whereas only 1 of the 7 patients (14.3%) with baseline pretreatment sarcopenia achieved a partial response (P =.069). Conclusion Neoadjuvant axitinib resulted in a decrease in skeletal muscle and subcutaneous adipose tissue, as well as weight loss. Patients with baseline sarcopenia tended to have a lower response rate to neoadjuvant axitinib.
UR - http://www.scopus.com/inward/record.url?scp=85028352684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028352684&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2017.05.056
DO - 10.1016/j.urology.2017.05.056
M3 - Article
C2 - 28705573
AN - SCOPUS:85028352684
SN - 0090-4295
VL - 108
SP - 114
EP - 121
JO - Urology
JF - Urology
ER -